Clinical Trial Update: First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

View source ↗

Summary

A completed clinical trial evaluating first-line FOLFOXIRI plus bevacizumab in patients with BRAF-mutant metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Azienda Ospedaliero, Universitaria Pisana | Conditions: Metastatic Colorectal Cancer | Status: COMPLETED